Illumina (ILMN) – Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for Illumina (NASDAQ: ILMN):

• 2/11/2025 – Illumina had its price target lowered by analysts at Morgan Stanley from $150.00 to $136.00. They now have an “equal weight” rating on the stock.
• 2/10/2025 – Illumina was downgraded by analysts at Barclays PLC from an “equal weight” rating to an “underweight” rating. They now have a $100.00 price target on the stock, down previously from $130.00.
• 2/10/2025 – Illumina had its price target raised by analysts at Piper Sandler from $185.00 to $190.00. They now have an “overweight” rating on the stock.
• 2/7/2025 – Illumina had its price target lowered by analysts at Royal Bank of Canada from $250.00 to $247.00. They now have an “outperform” rating on the stock.
• 2/7/2025 – Illumina had its price target lowered by analysts at Canaccord Genuity Group Inc. from $145.00 to $135.00. They now have a “hold” rating on the stock.
• 2/7/2025 – Illumina was downgraded by analysts at TD Cowen from a “buy” rating to a “hold” rating. They now have a $140.00 price target on the stock, down previously from $177.00.
• 2/7/2025 – Illumina had its price target lowered by analysts at Guggenheim from $170.00 to $150.00. They now have a “buy” rating on the stock.
• 2/3/2025 – Illumina had its price target lowered by analysts at Barclays PLC from $145.00 to $130.00. They now have an “equal weight” rating on the stock.
• 1/13/2025 – Illumina had its price target lowered by analysts at Morgan Stanley from $156.00 to $150.00. They now have an “equal weight” rating on the stock.

Illumina Stock Down 0.3 %

Shares of ILMN stock traded down $0.24 during trading hours on Monday, hitting $93.96. 3,252,699 shares of the company were exchanged, compared to its average volume of 2,611,130. Illumina, Inc. has a 52 week low of $92.20 and a 52 week high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average of $127.98 and a two-hundred day moving average of $134.22. The company has a market capitalization of $14.88 billion, a PE ratio of -12.23, a PEG ratio of 1.60 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Illumina

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Empowered Funds LLC grew its stake in shares of Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after acquiring an additional 66 shares in the last quarter. Bank of Stockton grew its position in Illumina by 3.8% in the fourth quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after purchasing an additional 80 shares in the last quarter. Caprock Group LLC grew its position in Illumina by 3.0% in the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock valued at $376,000 after purchasing an additional 83 shares in the last quarter. Integrated Advisors Network LLC increased its stake in Illumina by 2.0% in the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after buying an additional 90 shares during the last quarter. Finally, Stephens Inc. AR lifted its position in Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock worth $885,000 after buying an additional 90 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.